245 related articles for article (PubMed ID: 22955330)
21. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.
Eom KS; Shin SH; Yoon JH; Yahng SA; Lee SE; Cho BS; Kim YJ; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Lee S
Am J Hematol; 2013 Aug; 88(8):634-41. PubMed ID: 23620000
[TBL] [Abstract][Full Text] [Related]
22. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis.
Dreger P; Brand R; Milligan D; Corradini P; Finke J; Lambertenghi Deliliers G; Martino R; Russell N; van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2005 Jun; 19(6):1029-33. PubMed ID: 15830011
[TBL] [Abstract][Full Text] [Related]
23. Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Hebenstreit K; Iacobelli S; Leiblein S; Eisfeld AK; Pfrepper C; Heyn S; Vucinic V; Franke GN; Krahl R; Fricke S; Becker C; Pönisch W; Behre G; Niederwieser D; Lange T
Leuk Lymphoma; 2014 Jun; 55(6):1274-80. PubMed ID: 23964650
[TBL] [Abstract][Full Text] [Related]
24. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
25. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
[TBL] [Abstract][Full Text] [Related]
26. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.
Toze CL; Dalal CB; Nevill TJ; Gillan TL; Abou Mourad YR; Barnett MJ; Broady RC; Forrest DL; Hogge DE; Nantel SH; Power MM; Song KW; Sutherland HJ; Smith CA; Narayanan S; Young SS; Connors JM; Shepherd JD
Br J Haematol; 2012 Jul; 158(2):174-185. PubMed ID: 22640008
[TBL] [Abstract][Full Text] [Related]
28. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
29. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Kebriaei P; Detry MA; Giralt S; Carrasco-Yalan A; Anagnostopoulos A; Couriel D; Khouri IF; Anderlini P; Hosing C; Alousi A; Champlin RE; de Lima M
Blood; 2007 Nov; 110(9):3456-62. PubMed ID: 17652620
[TBL] [Abstract][Full Text] [Related]
31. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Chavez JC; Kharfan-Dabaja MA; Kim J; Yue B; Dalia S; Pinilla-Ibarz J; Anasetti C; Locke FL
Leuk Res; 2014 Oct; 38(10):1165-72. PubMed ID: 24889511
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia.
Jindra P; Raida L; Lysak D; Karas M; Papajik T; Jungova A; Mohammadová L; Houdova L
Neoplasma; 2016; 63(4):595-600. PubMed ID: 27268923
[TBL] [Abstract][Full Text] [Related]
33. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
34. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.
Khouri IF; Bassett R; Poindexter N; O'Brien S; Bueso-Ramos CE; Hsu Y; Ferrajoli A; Keating MJ; Champlin R; Fernandez-Vina M
Cancer; 2011 Oct; 117(20):4679-88. PubMed ID: 21455998
[TBL] [Abstract][Full Text] [Related]
35. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
Poiré X; Labopin M; Cornelissen JJ; Volin L; Richard Espiga C; Veelken JH; Milpied N; Cahn JY; Yacoub-Agha I; van Imhoff GW; Michallet M; Michaux L; Nagler A; Mohty M
Am J Hematol; 2015 Aug; 90(8):719-24. PubMed ID: 26010466
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
Bertz H; Illerhaus G; Veelken H; Finke J
Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.
Boyiadzis M; Foon KA; Pavletic S
Expert Opin Biol Ther; 2007 Dec; 7(12):1789-97. PubMed ID: 18034645
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
[TBL] [Abstract][Full Text] [Related]
39. Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over.
Santoro N; Labopin M; Ciceri F; Van Lint MT; Nasso D; Blaise D; Arcese W; Tischer J; Bruno B; Ehninger G; Koc Y; Santarone S; Huang XJ; Savani BN; Mohty M; Ruggeri A; Nagler A
Cancer; 2019 May; 125(9):1499-1506. PubMed ID: 30620383
[TBL] [Abstract][Full Text] [Related]
40. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Sorror ML; Storer BE; Sandmaier BM; Maris M; Shizuru J; Maziarz R; Agura E; Chauncey TR; Pulsipher MA; McSweeney PA; Wade JC; Bruno B; Langston A; Radich J; Niederwieser D; Blume KG; Storb R; Maloney DG
J Clin Oncol; 2008 Oct; 26(30):4912-20. PubMed ID: 18794548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
